Merck is set to share pivotal new data on its HIV treatment and prevention pipeline at the upcoming European AIDS Conference, highlighting the company’s commitment to addressing this global health challenge. These findings could significantly impact treatment strategies and patient outcomes in the HIV landscape, making this an important event for stakeholders in the healthcare sector.
RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conference (EACS 2025) taking place Oct.15-18, 2025, in Paris, France. The company’s presentations will include: An oral presentation of weight and body composition at Week 48 from the Phase 3 trial (MK-8591A-052) comparing doravirine/islatravir [DOR/ISL (100mg/0.25mg)] v
Source: Original Press Release
